Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday. The late-stage trial on tirzepatide, the active ingredient in the company’s weight loss injection Zepbound and diabetes…
Dr. Scott Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. He is a CNBC contributor and is a member of the boards of Pfizer and several other startups in health and tech. He is also a partner at the venture capital firm New Enterprise Associates. Shani…
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The agency greenlighted the therapy, which will be marketed as Winrevair, for adults with pulmonary arterial hypertension. The decision…
Read More “FDA approves Merck’s drug for rare, deadly lung condition” »
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, putting the shot on track to be available in the U.S. this fall….
The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January 20, 2023. Eisai | via Reuters Medicare has agreed to pay for the Alzheimer’s treatment Leqembi, a major turning point for patients who are diagnosed with the early stages of the disease. Leqembi is the only drug on the…
Read More “Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know” »
